full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for May, 2014

31
May

Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering from advanced non-small cell lung cancer. And analysts quickly heralded the data, saying it should help pave the way to quickly broaden the market for this drug. …read more […]

31
May

AbbVie’s experimental leukemia drug ABT-199 is continuing to wow analysts with some stellar early-stage data. At the interim point of a Phase Ib study, ABT-199/GDC-0199 combined with rituximab registered an 84% overall response rate among patients with chronic lymphocytic leukemia. …read more Source: AbbVie’s leukemia drug program continues to wow analysts in early study     

31
May

Today, Roche put out the word that their PD-L1 drug MPDL3280A won the FDA’s coveted breakthrough therapy designation, potentially putting it on an inside track at the agency, which has been hurrying along new medicines in the pipeline. …read more Source: Roche partners with Roche on ‘breakthrough’ PD-L1 cancer program     

30
May

Citing “usually well-informed sources,” the Financial Times reports that Shire is considering a $4 billion bid for rare disease specialist NPS Pharma, a deal that would bolster the company’s last blockbuster acquisition and perhaps get it out of rivals’ crosshairs. …read more Source: Buzz: Shire eyes NPS for $4B amid an M&A blitz     

30
May

As Europe prepares to open its clinical trial data vaults in a move toward greater transparency, the British Medical Journal is criticizing the European Medicines Agency for seemingly backtracking on its promises to make important information available to consumers. …read more Source: BMJ accuses EMA of watering down open trial data policy     

30
May

Among the lasting echoes of AstraZeneca’s now-cooled M&A gamesmanship with Pfizer is a promise to grow sales a whopping 75% over 10 years, expecting to reach $45 billion by 2023. That sky-high estimate depends largely on the company’s pipeline cancer treatments, and this weekend’s meeting of the American Society of Clinical Oncology will shine a […]

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off